Mavrilimumab: An evidence based review of its potential in the treatment of rheumatoid arthritis

Core Evidence

Volumn 9, Issue , 2014, Pages 41-48

  Di Franco, Manuela ^a   Gerardi, Maria Chiara ^a   Lucchino, Bruno ^a   Conti, Fabrizio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

GM CSF; Mavrilimumab; Rheumatoid arthritis

Indexed keywords

CAM 3001; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAVRILIMUMAB; UNCLASSIFIED DRUG;

BACKACHE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT OUTCOME; URTICARIA; VIRUS INFECTION;

EID: 84897013293     PISSN: 1555175X     EISSN: None     Source Type: Journal    
DOI: 10.2147/CE.S39770     Document Type: Review

References (41)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
2. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res(Hoboken). 2012;64(5):625-639.
3. O'Dell JR, Mikuls TR, Taylor TH, et al; CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307-318.
4. Papagoras C, Voulgari PV, Drosos AA. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev. 2010;9(8):574-582.
5. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533-544. (Pubitemid 351913679)
6. Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. 2001;15(4):557-567. (Pubitemid 33016441)
7. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A. 1994;91(12):5592-5596. (Pubitemid 24174374)
8. Bagby GC Jr, Dinarello CA, Wallace P, Wagner C, Hefeneider S, McCall E. Interleukin 1 stimulates granulocyte macrophage colony-stimulating activity release by vascular endothelial cells. J Clin Invest. 1986;78(5):1316-1323. (Pubitemid 17181571)
9. Leizer T, Cebon J, Layton JE, Hamilton JA. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood. 1990;76(10):1989-1996.
10. Campbell IK, Novak U, Cebon J, Layton JE, Hamilton JA. Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1. J Immunol. 1991; 147(4):1238-1246.
11. Filonzi EL, Zoellner H, Stanton H, Hamilton JA. Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage colony-stimulating factor production in human arterial smooth muscle cells. Atherosclerosis. 1993;99(2):241-252. (Pubitemid 23130295)
12. Hamilton JA. Coordinate and noncoordinate colony stimulating factor formation by human monocytes. J Leukoc Biol. 1994;55(3):355-361. (Pubitemid 24097242)
13. Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor(GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006;16(2):126-133. (Pubitemid 43247967)
14. Lang RA, Metcalf D, Cuthbertson RA, et al. Transgenic mice expressing a hemopoietic growth factor gene(GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell. 1987;51(4):675-686.
15. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol. 1998;161(7): 3639-3644.
16. Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor(GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 2001;3(5): 293-298. (Pubitemid 32821522)
17. de Vries EG, Willemse PH, Biesma B, Stern AC, Limburg PC, Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet. 1991;338(8765):517-518.
18. Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Stern AC, Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood. 1989;74(8):2769-2770. (Pubitemid 20007805)
19. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996;39(1):115-124. (Pubitemid 26036386)
20. Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest. 1989;83(3):876-882. (Pubitemid 19080619)
21. Fiehn C, Wermann M, Pezzutto A, Hüfner M, Heilig B. [Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy]. Z Rheumatol. 1992;51(3):121-126. German.
22. Singh JA, Pando JA, Tomaszewski J, Schumacher HR. Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naïve patients. J Rheumatol. 2004;31(7):1281-1285. (Pubitemid 38879189)
23. Bresnihan B, Gerlag DM, Rooney T, et al. Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol. 2007;34(3):620-622. (Pubitemid 46364021)
24. Bresnihan B, Pontifex E, Thurlings RM, et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol. 2009;36(8):1800-1802.
25. Nair JR, Edwards SW, Moots RJ. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy. Expert Opin Biol Ther. 2012;12(12): 1661-1668.
26. Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis. 2011;70(9):1542-1549.
27. Burmester GR, Weinblatt ME, McInnes IB, et al; EARTH Study Group. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013;72(9):1445-1452.
28. Felson DT, Anderson JJ, Boers JJ et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-735.
29. A study of mavrilimumab in subjects with moderate-to-severe rheumatoid arthritis [webpage on the Internet]. Bethesda, MD: ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01706926?term= mavrilimumab&rank=2. Accessed October 19, 2013.
30. A long term safety study of mavrilimumab in adult subjects with rheumatoid arthritis [webpage on the Internet]. Bethesda, MD: ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT01712399?term=mavrilimumab&rank=3. Accessed October 19, 2013.
31. A study of mavrilimumab versus anti tumour necrosis factor in subjects with rheumatoid arthritis [webpage on the Internet]. Bethesda, MD: ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT01715896?term=mavrilimumab&rank=1. Accessed October 19, 2013.
32. A study of the safety and preliminary efficacy of MOR103, a human antibody to granulocyte macrophage colony-stimulating factor(GM-CSF), in patients with active rheumatoid arthritis [webpage on the Internet]. Bethesda, MD: ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ study/NCT01023256?term=MOR103&rank=1. Accessed September 30, 2013.
33. Study of KB003 in biologics-inadequate rheumatoid arthritis [webpage on the Internet]. Bethesda, MD: ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00995449?term=kb003&rank=2. Accessed September 30, 2013.
34. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45. (Pubitemid 36091645)
35. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253-259. (Pubitemid 29063266)
36. Keystone E, Heijde DV, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319-3329.
37. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-876. (Pubitemid 46768126)
38. Smolen JS, Beaulieu A, Rubbert-Roth A, et al OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis(OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-997. (Pubitemid 351392039)
39. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev. 2010;233(1):301-312.
40. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology(Oxford). 2012;51 Suppl 6:vi37-vi43.
41. Smolen JS, Aletaha D, Bijlsma JW, et al; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637.